AMODIO, Nicola
 Distribuzione geografica
Continente #
NA - Nord America 2.765
AS - Asia 2.595
EU - Europa 1.242
SA - Sud America 568
AF - Africa 36
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 3
Totale 7.225
Nazione #
US - Stati Uniti d'America 2.667
SG - Singapore 1.263
CN - Cina 632
IT - Italia 594
BR - Brasile 455
IN - India 268
VN - Vietnam 253
SE - Svezia 202
GB - Regno Unito 120
DE - Germania 107
CA - Canada 70
AR - Argentina 47
FI - Finlandia 42
HK - Hong Kong 35
BD - Bangladesh 28
EC - Ecuador 26
RO - Romania 26
ID - Indonesia 21
RU - Federazione Russa 21
MX - Messico 20
PL - Polonia 19
UA - Ucraina 19
NL - Olanda 18
EU - Europa 15
CL - Cile 14
JP - Giappone 14
CZ - Repubblica Ceca 13
EG - Egitto 13
FR - Francia 13
IQ - Iraq 13
ES - Italia 11
ZA - Sudafrica 10
IR - Iran 9
PY - Paraguay 9
VE - Venezuela 9
PK - Pakistan 8
TR - Turchia 8
AE - Emirati Arabi Uniti 7
AT - Austria 7
LT - Lituania 6
CH - Svizzera 5
GR - Grecia 5
SA - Arabia Saudita 5
YE - Yemen 5
JO - Giordania 4
CO - Colombia 3
EE - Estonia 3
IL - Israele 3
MY - Malesia 3
NP - Nepal 3
PA - Panama 3
TN - Tunisia 3
UZ - Uzbekistan 3
AU - Australia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
HN - Honduras 2
KE - Kenya 2
KW - Kuwait 2
NO - Norvegia 2
PE - Perù 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CV - Capo Verde 1
ET - Etiopia 1
GE - Georgia 1
HR - Croazia 1
IE - Irlanda 1
LB - Libano 1
MA - Marocco 1
MK - Macedonia 1
NG - Nigeria 1
NR - Nauru 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
TL - Timor Orientale 1
TT - Trinidad e Tobago 1
Totale 7.225
Città #
Singapore 441
Chandler 388
Santa Clara 233
Dallas 231
Hefei 225
Bengaluru 219
Lawrence 189
Milan 189
Princeton 189
Beijing 150
Catanzaro 134
Ashburn 115
Ho Chi Minh City 112
Wilmington 106
London 88
Chicago 86
Munich 84
Des Moines 57
Hanoi 48
Ottawa 47
São Paulo 43
Boardman 35
Hong Kong 35
Turku 34
Los Angeles 25
Rio de Janeiro 24
Shanghai 24
Redwood City 20
Brooklyn 19
Warsaw 18
Guangzhou 16
New York 16
Rome 16
San Francisco 15
Council Bluffs 14
Haiphong 14
Horia 14
Pune 14
The Dalles 14
Naples 13
Norwalk 13
Olomouc 12
Phoenix 12
Stockholm 12
Boston 11
Hanover 10
Redmond 10
San Jose 10
Timisoara 10
Bari 9
Cosenza 9
Curitiba 9
Da Nang 9
Montreal 9
Chennai 8
Columbus 8
Helsinki 8
Manchester 8
Porto Alegre 8
Quito 8
Ann Arbor 7
Biên Hòa 7
Charlotte 7
Dhaka 7
Guayaquil 7
Jiaxing 7
Lamezia Terme 7
Mexico City 7
Ovada 7
San Nicola Manfredi 7
Settingiano 7
Shenzhen 7
Atlanta 6
Baghdad 6
Belo Horizonte 6
Johannesburg 6
Palermo 6
Parma 6
Reggio Calabria 6
Thái Bình 6
Tokyo 6
Uberlândia 6
West Jordan 6
Andover 5
Ankara 5
Augusta 5
Aversa 5
Campinas 5
Contagem 5
Nanjing 5
Recife 5
Salvador 5
Sanaa 5
São Bernardo do Campo 5
Abaetetuba 4
Amman 4
Amsterdam 4
Asunción 4
Brasília 4
Cairo 4
Totale 4.176
Nome #
miR-22 suppresses DNA ligase III addiction in multiple myeloma 95
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 84
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 72
Mitochondrial dysfunction at the crossroad of cardiovascular diseases and cancer 69
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 69
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 68
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 67
Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells 65
Radiation induced by-stander effect: possible RNA implication in DNA damage transmission? 63
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 62
IL-6 Receptor Blockade by Tocilizumab Has Anti-absence and Anti-epileptogenic Effects in the WAG/Rij Rat Model of Absence Epilepsy 62
MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence 58
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 57
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 57
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 57
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 57
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. (CO-FIRST AUTHOR) 57
Turning Stem Cells Bad: Generation of Clinically Relevant Models of Human Acute Myeloid Leukemia through Gene Delivery- or Genome Editing-Based Approaches 56
Early Hematopoietic Zinc Finger protein (EHZF), the human homologue to Evi3, is highly expressed in primitive human hematopoietic cells 56
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 55
Jagged ligands enhance the pro-angiogenic activity of multiple myeloma cells 55
Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats 54
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 53
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment 53
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 53
Oleil hydroxytyrosol (Htol) exerts anti-myeloma activity by antagonizing key survival pathways in malignant plasma cells (CO-FIRST AUTHOR) 53
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 52
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 52
Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma 51
Early hematopoietic zinc finger protein, a novel transcription co-factor with a potential role in haematopoietic homeostasis and leukaemogenesis 51
In Vitro Silencing of lncRNAs Using LNA GapmeRs 51
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer 50
TARGETING OF DEREGULATED LNCRNA NEAT1 AFFECTS MULTIPLE MYELOMA ACTIVITY 50
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 50
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer. 50
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 49
Zinc finger protein 521 antagonizes early B-cell factor 1 and modulates the B-lymphoid differentiation of primary hematopoietic progenitors 49
Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma. 49
Cateslytin abrogates lipopolysaccharide-induced cardiomyocyte injury by reducing inflammation and oxidative stress through toll like receptor 4 interaction 49
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 48
Ex-vivo characterization of circulating colon cancer cells distinguished in stem and differentiated subset provides useful biomarker for personalized metastatic risk assessment 48
Non-coding RNA: A novel opportunity for the personalized treatment of multiple myeloma 48
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 48
P21-ACTIVATED KINASE 4 (PAK4) REGULATES MULTIPLE MYELOMA (MM) CELL GROWTH AND SURVIVAL BY MODULATION OF CRITICAL TRANSCRIPTIONAL PATHWAYS: THERAPEUTIC APPLICATION OF PAK4 ALLOSTERIC INHIBITORS 48
Contribution of PKB/AKT signaling to thyroid cancer 48
CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network 48
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 48
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 47
A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells 47
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 47
Inhibitor of DNA binding 2 (ID2) regulates key transcriptional programs in multiple myeloma 46
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 45
Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. 45
Znf521 enhances mll‐af9‐dependent hematopoietic stem cell transformation in acute myeloid leukemias by altering the gene expression landscape† 45
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 44
Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment. 44
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 43
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 43
miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies 43
ZINC FINGER PROTEIN 521 (EHZF/ZNF521) ANTAGONIZES EARLY B-CELL FACTOR 1 AND MODULATES THE B-LYMPHOID DIFFERENTIATION OF PRIMARY HEMATOPOIETIC PROGENITORS 43
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity 43
Alternative non-homologous end joining DNA repair as therapeutic target in multiple myeloma 43
A 13 mer LNA miR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells 43
Phoenixin-14: detection and novel physiological implications in cardiac modulation and cardioprotection 43
Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells 43
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 43
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth 42
Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart 42
Protective role of GPER agonist g-1 on cardiotoxicity induced by doxorubicin 42
Activating E17K mutation in the gene encoding the protein kinase B/AKT in squamous cell carcinoma of the lung 42
The non-coding RNA landscape of plasma cell dyscrasias 42
Early hematopoietic zinc finger protein - zinc finger protein 521 (EHZF/ZNF521): a candidate regulator of diverse immature cells 41
Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation 40
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence 40
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 40
Biological Insights into Myeloma and Other B Cell Malignancies 40
miR-22 suppresses DNA ligase III addiction in multiple myeloma. 40
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 39
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia 39
Synthetic MiR-29b Mimics Potentiate Dendritic-Cell Based Immunotherapy Against Multiple Myeloma In Vitro and In Vivo 39
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 38
In vitro and vivo activity against multiple myeloma cells of a novel locked nucleic acid (LNA)-miR-221 inhibitor 38
In vitro expansion of tumour cells derived from blood and tumour tissue is useful to redefine personalized treatment in non-small cell lung cancer patients 38
Expression pattern and biological significance of the lncRNA ST3GAL6-AS1 in multiple myeloma 38
A Comparison of Different Sample Processing Protocols for MALDI Imaging Mass Spectrometry Analysis of Formalin-Fixed Multiple Myeloma Cells 37
Inhibition Of Mir-21 In HS-5 Bone Marrow Stromal Cells In The Presence Of Multiple Myeloma cells Restores RANKL/OPG Ratio: A Potential Therapeutic Approach For Myeloma-Related Bone Disease 37
Two red wine flavonoids, quercetin and myricetin, exert different myocardial and coronary actions through distinct intracellular pathways 37
Early Hematopoietic Zinc Finger (EHZF/ZNF521) prevents tumor cell recognition by Natural Killer Cells 37
The chromogranin A1-373 fragment reveals how a single change in the protein sequence exerts strong cardioregulatory effects by engaging neuropilin-1 37
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth 36
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells 36
SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells. 36
miR-29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma-related bone disease 36
Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma 36
Locked Nucleic Acid (LNA)-miR-221 inhibitor as a promising new anti-myeloma agent 36
null 36
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma 35
Early Hematopoietic Zinc Finger protein (EHZF), a novel co-transcription factor: functional properties, expression in myelogenous leukaemias and interactions with histone deacetylases 35
Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma 34
Selective targeting of IRF4 by sytnthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo 34
Totale 4.779
Categoria #
all - tutte 89.618
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.618


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021287 0 0 0 0 34 21 20 14 54 45 72 27
2021/2022569 23 2 5 154 38 13 24 113 54 61 71 11
2022/20231.183 386 64 71 68 100 93 5 87 163 51 70 25
2023/2024515 113 73 34 42 28 129 13 8 2 14 19 40
2024/20252.129 321 95 65 58 151 302 44 51 266 130 214 432
2025/20262.490 264 494 445 773 514 0 0 0 0 0 0 0
Totale 7.466